Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease

NCT02405442 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02405442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02405442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2015
Completion date
December 22, 2016
Enrollment
187 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease